Interactions between long-acting β2-agonists and glucocorticoids

Drug Discovery Today: Therapeutic Strategies

Volumn 3, Issue 3, 2006, Pages 261-268

  Caramori, Gaetano ^a   Ito, Kazuhiro ^b   Papi, Alberto ^a   Adcock, Ian M ^b  

^a UNIVERSITY OF FERRARA   (Italy)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CCAAT ENHANCER BINDING PROTEIN ALPHA; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; DNA; EOTAXIN; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; MUSCARINIC RECEPTOR BLOCKING AGENT; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; ROLIPRAM; SALMETEROL XINAFOATE; THEOPHYLLINE; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; CYTOKINE RELEASE; DISEASE CONTROL; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DNA RESPONSIVE ELEMENT; DNA SEQUENCE; DRUG MECHANISM; DRUG POTENTIATION; DRUG WITHDRAWAL; EOSINOPHIL COUNT; FORCED EXPIRATORY VOLUME; GENETIC TRANSCRIPTION; HUMAN; INDIVIDUALIZATION; INHIBITION KINETICS; LEUKOCYTE COUNT; LUNG FIBROBLAST; MAINTENANCE THERAPY; MEDIATOR RELEASE; MILD PERSISTENT ASTHMA; MORTALITY; NERVE STIMULATION; NONHUMAN; PATIENT CARE; PROMOTER REGION; PROTEIN PHOSPHORYLATION; QUALITY OF LIFE; RECEPTOR UPREGULATION; REVIEW; SENSORY NERVE; SEVERE PERSISTENT ASTHMA; SMOKING CESSATION; SYMPTOM; THRUSH; TREATMENT OUTCOME;

EID: 33751191434     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2006.09.002     Document Type: Review

References (52)

1. Barnes P.J. Corticosteroids: the drugs to beat. Eur. J. Pharmacol. 533 (2006) 2-14
2. Global Initiative for Asthma (2005) Global strategy for Asthma Management and Prevention. NHLBI/WHO Workshop report. 2002. NIH Publication 02-3659. Last update 2005. http://www.ginasthma.com (accessed April 2006)
3. Global Initiative for Chronic Obstructive Lung Disease (2006) Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO workshop report. Bethesda, National Heart, Lung and Blood Institute, April 2001; NIH Publication No 2701:1-100. Last update 2005. http://www.goldcopd.com (accessed April 2006)
4. Papi A. Investigating the steroids and long-acting beta 2-agonists combination: why do we need more?. Eur. Respir. J. 23 (2004) 501-502
5. Johnson M. Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation. J. Allergy Clin. Immunol. 117 (2006) 18-24
6. Mak J.C., Nishikawa M., Shirasaki H., Miyayasu K., and Barnes P.J. Protective effects of a glucocorticoid on downregulation of pulmonary beta 2-adrenergic receptors in vivo. J. Clin. Invest. 96 (1995) 99-106
7. Hadcock J.R., and Malbon C.C. Regulation of beta-adrenergic receptors by "permissive" hormones: glucocorticoids increase steady-state levels of receptor mRNA. Proc. Natl. Acad. Sci. U S A 85 (1988) 8415-8419
8. Adcock I.M., et al. Molecular interactions between glucocorticoids and long-acting beta2-agonists. J. Allergy Clin. Immunol. 110 (2002) S261-S268
9. 2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J. Biol. Chem. 274 (1999) 1005-1010
10. Usmani O.S., et al. Glucocorticoid Receptor Nuclear Translocation in Airway Cells Following Inhaled Combination Therapy. Am. J. Respir. Crit. Care Med. 172 (2005) 704-712
11. Haque R.A., et al. Effect of Salmeterol and Fluticasone on Glucocorticoid Receptor Translocation in Sputum Macrophages and Peripheral Blood Mononuclear Cells from Patients with Chronic Obstructive Pulmonary Disease. Proceedings of the American Thoracic Society 3 (2006) A848
12. Roth M., et al. Dysfunctional interaction of C/EBPα and the glucocorticoid receptor in asthmatic bronchial smooth-muscle cells. N. Engl. J. Med. 351 (2004) 560-574
13. Roth M., et al. Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronized cellular signaling. Lancet 360 (2002) 1293-1299
14. Bonacci J.V., and Stewart A.G. Regulation of human airway mesenchymal cell proliferation by glucocorticoids and beta2-adrenoceptor agonists. Pulm. Pharmacol. Ther. 19 (2006) 32-38
15. 2-agonists and corticosteroids on TNFα-induced interleukin 8 release from cultured human airway smooth muscle cells. Am. J. Respir. Cell. Mol. Biol. 22 (2000) 1-7
16. Nie M., et al. Beta2-Adrenoceptor agonists, like glucocorticoids, repress eotaxin gene transcription by selective inhibition of histone H4 acetylation. J. Immunol. 175 (2005) 478-486
17. Sarir H., et al. Cigarette-smoke induced IL8 production by human monocyte-derived macrophages: synergistic inhibition by fluticasone and salmeterol. Eur. Respir. J. 26 (2005) 145
18. Edwards M.R., et al. Combination therapy: Synergistic suppression of virus-induced chemokines in airway epithelial cells. Am. J. Respir. Cell. Mol. Biol. 34 (2006) 616-624
19. Dowling R.B., et al. Effect of fluticasone propionate and salmeterol on Pseudomonas aeruginosa infection of the respiratory mucosa in vitro. Eur. Respir. J. 14 (1999) 363-369
20. Fragaki K., et al. Downregulation by a long-acting beta2-adrenergic receptor agonist and corticosteroid of Staphylococcus aureus-induced airway epithelial inflammatory mediator production. Am. J. Physiol. Lung Cell. Mol. Physiol. 291 (2006) L11-L18
21. Sin D.D., and Man S.F. Corticosteroids and adrenoceptor agonists: the compliments for combination therapy in chronic airways diseases. Eur. J. Pharmacol. 533 (2006) 28-35
22. Sin D.D., et al. Pharmacological management to reduce exacerbations in adults with asthma: a systematic review and meta-analysis. JAMA. 292 (2004) 367-376
23. Overbeek S.E., et al. Formoterol added to low-dose budesonide has no additional anti-inflammatory effect in asthmatic patients. Chest. 128 (2005) 1121-1127
24. Koopmans J.G., et al. Adding salmeterol to an inhaled corticosteroid: long term effects on bronchial inflammation in asthma. Thorax. 61 (2006) 306-312
25. Koopmans J.G., et al. Adding salmeterol to an inhaled corticosteroid reduces allergen-induced serum IL-5 and peripheral blood eosinophils. J. Allergy Clin. Immunol. 116 (2005) 1007-1013
26. Barnes P.J., et al. Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet 363 (2004) 731-733
27. Tomlinson J.E., et al. Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma. Thorax. 60 (2005) 282-287
28. O'Byrne P.M., et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am. J. Respir. Crit. Care Med. 171 (2005) 129-136
29. Bateman E.D., et al., GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am. J. Respir. Crit. Care Med. 170 (2004) 836-844
30. Bateman E.D., et al. Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down. J. Allergy Clin. Immunol. 117 (2006) 563-570
31. Tarsin W.Y., et al. Emitted dose estimates from Seretide Diskus and Symbicort Turbuhaler following inhalation by severe asthmatics. Int. J. Pharm. 316 (2006) 131-137
32. Calverley P., et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 361 (2003) 449-456
33. Calverley P.M., et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur. Respir. J. 22 (2003) 912-919
34. Szafranski W., et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir. J. 21 (2003) 74-81
35. Nannini L., et al. Combined corticosteroid and long acting beta-agonist in one inhaler for chronic obstructive pulmonary disease. Cochrane Database Syst. (2004) Rev. CD003794
36. Barnes N.C., et al. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am. J. Respir. Crit. Care Med. 173 (2006) 736-743
37. Vestbo J., and TORCH Study Group. The TORCH (towards a revolution in COPD health) survival study protocol. Eur. Respir. J. 24 (2004) 206-210
38. Martinez F.D. Safety of long-acting beta-agonists--an urgent need to clear the air. N. Engl. J. Med. 353 (2005) 2637-2639
39. Borger P., et al. Abnormal Expression of Cell Cycle Regulators C/EBPα and C/EBPδ in Airway Smooth Muscle (ASM) Cells of Patients with Asthma and COPD. Proceedings of the American Thoracic Society 3 (2006) A825
40. Ito K., et al. Update on glucocorticoid action and resistance. J. Allergy Clin. Immunol. 117 (2006) 522-543
41. Szatmary Z., et al. Inhibition of glucocorticoid receptor-mediated transcriptional activation by p38 mitogen-activated protein (MAP) kinase. J. Biol. Chem. 279 (2004) 43708-43715
42. Burge P.S., et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 320 (2000) 1297-1303
43. Pauwels R.A., et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N. Engl. J. Med. 340 (1999) 1948-1953
44. Vestbo J., et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 353 (1999) 1819-1823
45. The Lung Health Study Research Group (2000) Effect of Inhaled Triamcinolone on the Decline in Pulmonary Function in Chronic Obstructive Pulmonary Disease. N. Engl. J. Med. 343, 1902-1909
46. Gizycki M.J., et al. Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue. Thorax 57 (2002) 799-803
47. Hanania N.A., et al. The efficacy and safety of fluticasone propionate (250 μg)/salmeterol (50 μg) combined in the Diskus inhaler for the treatment of COPD. Chest 124 (2003) 834-843
48. Hattotuwa K.L., et al. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am. J. Respir. Crit. Care. Med. 165 (2002) 1592-1596
49. Mahler D.A., et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care. Med. 166 (2002) 1084-1091
50. Paggiaro P.L., et al. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet 351 (1998) 773-780
51. Thompson W.H., et al. Controlled trial of inhaled fluticasone propionate in moderate to severe COPD. Lung 180 (2002) 191-201
52. Make B., et al. The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study. Clin. Ther. 27 (2005) 531-542